Anti-hepatitis c virus antibodies
AssigneeBar-Ilan University
InventorsMeital GAL-TANAMY, Gur YAARI, Shiri ELMEDVI, Sivan ELIYAHU, Oz SHARABI
Life of this patent
Estimating the term…
Abstract
Provided are isolated monoclonal antibodies or any antigen-binding fragment thereof which bind to hepatitis C virus E2 protein (HCV E2). In particular the presently claimed subject matter concerns neutralizing anti HCV E2 antibodies, and their use for treating HCV infection. Furthermore, the presently claimed subject matter concerns methods for preparing neutralizing anti HCV scFv antibodies associated with HCV clearance.
Claims23
An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to hepatitis C virus E2 protein (HCV E2), wherein said antibody is selected from a group consisting of:
- a. a monoclonal antibody comprising a heavy chain complementarity determining region (CDRH) 1 denoted by SEQ ID NO. 158, CDRH2 denoted by SEQ ID NO. 159, CDRH3 denoted by SEQ ID NO. 160, and the light chain complementarity determining region (CDRL) 1 denoted by SEQ ID NO. 163, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 165, or a variant thereof;
- b. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 168, CDRH2 denoted by SEQ ID NO. 169, CDRH3 denoted by SEQ ID NO. 170, and a CDRL1 denoted by SEQ ID NO. 173, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 175, or a variant thereof;
- c. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 108, CDRH2 denoted by SEQ ID NO. 109, CDRH3 denoted by SEQ ID NO. 110, and a CDRL1 denoted by SEQ ID NO. 113, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 115, or a variant thereof;
- d. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 78, CDRH2 denoted by SEQ ID NO. 79, CDRH3 denoted by SEQ ID NO. 80, and a CDRL1 denoted by SEQ ID NO. 83, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 85, or a variant thereof;
- e. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 59, CDRH2 denoted by SEQ ID NO. 60, CDRH3 denoted by SEQ ID NO. 61, and a CDRL1 denoted by SEQ ID NO. 64, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 66, or a variant thereof;
- f. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 69, CDRH2 denoted by SEQ ID NO. 70, CDRH3 denoted by SEQ ID NO. 182, and a CDRL1 denoted by SEQ ID NO. 73, a CDRL2 denoted by SEQ ID NO. 74, and a CDRL3 denoted by SEQ ID NO. 75, or a variant thereof;
- g. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 88, CDRH2 denoted by SEQ ID NO. 89, CDRH3 denoted by SEQ ID NO. 90, and a CDRL1 denoted by SEQ ID NO. 93, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 95, or a variant thereof;
- h. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 98, CDRH2 denoted by SEQ ID NO. 99, CDRH3 denoted by SEQ ID NO. 100, and a CDRL1 denoted by SEQ ID NO. 103, a CDRL2 denoted by SEQ ID NO. 104, and a CDRL3 denoted by SEQ ID NO. 105, or a variant thereof;
- i. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 118, CDRH2 denoted by SEQ ID NO. 119, CDRH3 denoted by SEQ ID NO. 120, and a CDRL1 denoted by SEQ ID NO. 123, a CDRL2 denoted by SEQ ID NO. 124, and a CDRL3 denoted by SEQ ID NO. 125, or a variant thereof;
- j. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 128, CDRH2 denoted by SEQ ID NO. 129, CDRH3 denoted by SEQ ID NO. 130, and a CDRL1 denoted by SEQ ID NO. 133, a CDRL2 denoted by SEQ ID NO. 134, and a CDRL3 denoted by SEQ ID NO. 135, or a variant thereof;
- k. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 138, CDRH2 denoted by SEQ ID NO. 139, CDRH3 denoted by SEQ ID NO. 140, and a CDRL1 denoted by SEQ ID NO. 143, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 145, or a variant thereof;
- and
- l. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 148, CDRH2 denoted by SEQ ID NO. 149, CDRH3 denoted by SEQ ID NO. 150, and a CDRL1 denoted by SEQ ID NO. 153, a CDRL2 denoted by SEQ ID NO. 104, and a CDRL3 denoted by SEQ ID NO. 155, or a variant thereof.
An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to HCV E2, wherein said antibody comprises a heavy chain variable region and a light chain variable region, wherein said heavy chain variable region is encoded by a nucleic acid sequence which is at least 70% identical to the nucleic acid sequence denoted by SEQ ID NO. 156, SEQ ID NO. 166, SEQ ID NO. 106, SEQ ID NO. 76, SEQ ID NO. 57, SEQ ID NO. 67, SEQ ID NO. 86, SEQ ID NO. 96, SEQ ID NO. 116, SEQ ID NO. 126, SEQ ID NO. 136, SEQ ID NO. 146, and wherein said light chain variable region is encoded by a nucleic acid sequence which is at least 70% identical to SEQ ID NO. 161, SEQ ID NO. 171, SEQ ID NO. 111, SEQ ID NO. 81, SEQ ID NO. 62, SEQ ID NO. 71, SEQ ID NO. 91, SEQ ID NO. 101, SEQ ID NO. 121, SEQ ID NO. 131, SEQ ID NO. 141, SEQ ID NO. 151.
(canceled)
-10. (canceled)
A method of preparing neutralizing anti HCV scFv antibodies associated with HCV clearance, comprising the steps of:
- a. constructing a phage display scFv antibody library from peripheral blood mononuclear cells (PBMC) obtained from Spontaneous clearer (SC) individuals;
- b. identifying at least one HCV E2 binder;
- c. comparing the sequence of the at least one HCV E2 binder with the sequences in stratifying clusters from a general repertoire that are associated with HCV clearance;
- d. selecting an scFv sequence with high similarity to a sequence in a stratifying cluster from said general repertoire that is associated with HCV clearance.
(canceled)
Dependencies are inferred from the claim text.